お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
995316

緑内障治療の市場規模調査:適応症別、タイプ別、販売チャネル別-2026年までの世界予測-COVID-19の累積的影響

Glaucoma Treatment Market Research Report by Indication, by Type, by Sales Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
緑内障治療の市場規模調査:適応症別、タイプ別、販売チャネル別-2026年までの世界予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の緑内障治療の市場規模は、2020年の52億8167万米ドルから、2025年末までに76億9167万米ドルに成長すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮したCOVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

当レポートでは、緑内障治療市場を調査し、市場概要、市場の成長要因および阻害要因の分析、適応症別、タイプ別、販売チャネル別、地域別の市場規模の推移と予測、COVID-19の累積的影響、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場の見通し
  • 販売チャネル別の見通し
  • 適応症別の見通し
  • タイプ別の見通し
  • 地域別の見通し
  • 競合他社別の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 適応症別の世界の緑内障治療市場

  • 閉塞隅角緑内障
  • 先天性緑内障
  • 開放隅角緑内障
  • 続発性緑内障

第7章 タイプ別の世界の緑内障治療市場

  • アルファアゴニスト
  • ベータ遮断薬
  • 炭酸脱水酵素阻害剤
  • コリン作動性
  • 併用薬
  • プロスタグランジン類似体

第8章 販売チャネル別の世界の緑内障治療市場

  • 病院薬局
  • オンライン販売
  • 小売薬局

第9章 南北アメリカの緑内障治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋緑内障治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州・中東・アフリカの緑内障治療市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • AbbVie Inc.
  • Accutome, Inc
  • Aerie Pharmaceuticals Inc.
  • Akorn, Inc.
  • Alcon
  • Amorphex Therapeutics LLC
  • Asico, LLC
  • Bausch + Lomb
  • Bayer AG
  • Carl Zeiss Meditec AG
  • Fera Pharmaceuticals
  • Glaukos Corporation
  • Inotek Pharmaceuticals
  • Lumenis
  • Merck & Co, Inc.
  • Mobius Therapeutics, LLC
  • NIDEK CO., LTD.
  • Novartis International AG
  • Ocular Therapeutix
  • Perrigo Co. PLC
  • Pfizer, Inc.
  • pSivida Corp.
  • Quantel Medical
  • Santen Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Topcon Medical Systems

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2026
  • FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2026
  • FIGURE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, 2018-2026 (USD MILLION)
  • FIGURE 29. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, 2018-2026 (USD MILLION)
  • FIGURE 31. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2020 VS 2026 (%)
  • FIGURE 35. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2026
  • FIGURE 37. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 38. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, 2018-2026 (USD MILLION)
  • FIGURE 40. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 42. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 43. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 44. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 46. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 59. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 60. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 61. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 70. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 72. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 80. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 81. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 82. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. GLOBAL GLAUCOMA TREATMENT MARKET: FPNV POSITIONING MATRIX
  • FIGURE 84. GLOBAL GLAUCOMA TREATMENT MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 85. GLOBAL GLAUCOMA TREATMENT MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL GLAUCOMA TREATMENT MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL GLAUCOMA TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. CALIFORNIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. FLORIDA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. ILLINOIS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. NEW YORK GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. OHIO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. PENNSYLVANIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. TEXAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. GLOBAL GLAUCOMA TREATMENT MARKET: SCORES
  • TABLE 126. GLOBAL GLAUCOMA TREATMENT MARKET: BUSINESS STRATEGY
  • TABLE 127. GLOBAL GLAUCOMA TREATMENT MARKET: PRODUCT SATISFACTION
  • TABLE 128. GLOBAL GLAUCOMA TREATMENT MARKET: RANKING
  • TABLE 129. GLOBAL GLAUCOMA TREATMENT MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 130. GLOBAL GLAUCOMA TREATMENT MARKET: SHARE, BY COMPANY, 2020
  • TABLE 131. GLOBAL GLAUCOMA TREATMENT MARKET: MERGER & ACQUISITION
  • TABLE 132. GLOBAL GLAUCOMA TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 133. GLOBAL GLAUCOMA TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 134. GLOBAL GLAUCOMA TREATMENT MARKET: INVESTMENT & FUNDING
  • TABLE 135. GLOBAL GLAUCOMA TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 136. GLOBAL GLAUCOMA TREATMENT MARKET: LICENSE & PRICING
  • TABLE 137. GLOBAL GLAUCOMA TREATMENT MARKET: CONTACT DETAILS
目次
Product Code: MRR-430D3EB72952

The Global Glaucoma Treatment Market size was estimated at USD 5,281.67 Million in 2020 and expected to reach USD 5,720.45 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.64% to reach USD 8,686.75 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Glaucoma Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indication, the Glaucoma Treatment Market was studied across Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma, and Secondary Glaucoma.

Based on Type, the Glaucoma Treatment Market was studied across Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, Combined Medications, and Prostaglandin Analogs.

Based on Sales Channel, the Glaucoma Treatment Market was studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.

Based on Geography, the Glaucoma Treatment Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Glaucoma Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Glaucoma Treatment Market, including AbbVie Inc., Accutome, Inc, Aerie Pharmaceuticals Inc., Akorn, Inc., Alcon, Amorphex Therapeutics LLC, Asico, LLC, Bausch + Lomb, Bayer AG, Carl Zeiss Meditec AG, Fera Pharmaceuticals, Glaukos Corporation, Inotek Pharmaceuticals, Lumenis, Merck & Co, Inc., Mobius Therapeutics, LLC, NIDEK CO., LTD., Novartis International AG, Ocular Therapeutix, Perrigo Co. PLC, Pfizer, Inc., pSivida Corp., Quantel Medical, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Limited, and Topcon Medical Systems.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Glaucoma Treatment Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Glaucoma Treatment Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Glaucoma Treatment Market?
  • 4. What is the competitive strategic window for opportunities in the Global Glaucoma Treatment Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Glaucoma Treatment Market?
  • 6. What is the market share of the leading vendors in the Global Glaucoma Treatment Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Glaucoma Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Sales Channel Outlook
  • 3.4. Indication Outlook
  • 3.5. Type Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population coupled with rising incidences of glaucoma
      • 5.1.1.2. Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
      • 5.1.1.3. Potential rise in the use of smart gadgets and screen time among the population
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of early diagnosis with no pain or symptoms
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancement with eye drops as primary treatment
      • 5.1.3.2. Increasing research and development expenditure from several pharmaceutical and biotechnological companies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns with drug recalls
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Glaucoma Treatment Market, by Indication

  • 6.1. Introduction
  • 6.2. Angle Closure Glaucoma
  • 6.3. Congenital Glaucoma
  • 6.4. Open Angle Glaucoma
  • 6.5. Secondary Glaucoma

7. Glaucoma Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Alpha Agonist
  • 7.3. Beta Blockers
  • 7.4. Carbonic Anhydrase Inhibitors
  • 7.5. Cholinergic
  • 7.6. Combined Medications
  • 7.7. Prostaglandin Analogs

8. Glaucoma Treatment Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Sales
  • 8.4. Retail Pharmacies

9. Americas Glaucoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Glaucoma Treatment Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Glaucoma Treatment Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AbbVie Inc.
  • 13.2. Accutome, Inc
  • 13.3. Aerie Pharmaceuticals Inc.
  • 13.4. Akorn, Inc.
  • 13.5. Alcon
  • 13.6. Amorphex Therapeutics LLC
  • 13.7. Asico, LLC
  • 13.8. Bausch + Lomb
  • 13.9. Bayer AG
  • 13.10. Carl Zeiss Meditec AG
  • 13.11. Fera Pharmaceuticals
  • 13.12. Glaukos Corporation
  • 13.13. Inotek Pharmaceuticals
  • 13.14. Lumenis
  • 13.15. Merck & Co, Inc.
  • 13.16. Mobius Therapeutics, LLC
  • 13.17. NIDEK CO., LTD.
  • 13.18. Novartis International AG
  • 13.19. Ocular Therapeutix
  • 13.20. Perrigo Co. PLC
  • 13.21. Pfizer, Inc.
  • 13.22. pSivida Corp.
  • 13.23. Quantel Medical
  • 13.24. Santen Pharmaceutical Co., Ltd.
  • 13.25. Teva Pharmaceutical Industries Limited
  • 13.26. Topcon Medical Systems

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.